Current approaches and problems in malaria vaccine development

摘要

The overall objective of this review article is to visualize the current immunological approach in malaria vaccine development which provides a realistic prediction of various disputes against this parasitic disease. Recently, there is no licensed or approved vaccine from food and drug administration (FDA) or world health organization (WHO) against any human parasitic disease. There are number of parasitic diseases especially Plasmodium falciparum (malaria), a major cause of infectious mortality, represents a great challenge for parasitic vaccine development for human use. Inspite of extreme research in area of malaria vaccine development, there is no commercial vaccine (except Mosquirix, RTS, S; approved by European regulators, July 2015) available for malaria, parasitic disease. Recently, subunit vaccine constructs (> 20) are being evaluated in clinical trials or in advanced stage of preclinical development. For the last so many years, scientists identified probable target of parasitic disease and turn promising ones into malaria vaccine that can be evaluated.